# Enhanced Asthma Exacerbation â€“ Interactive Clinical Protocol

**Primary Guidelines:**
- Global Initiative for Asthma (GINA) 2025 Strategy Report[1][5][9]
- UpToDate: Acute Exacerbations of Asthma in Adults 2025
- NHLBI Asthma Care Quick Reference 2025[4]
- American Academy of Family Physicians Asthma Guidelines 2025

**Official Sources:**
- GINA 2025: https://ginasthma.org/2025-gina-strategy-report/
- UpToDate Clinical Decision Support: Asthma Exacerbation Management

## ENHANCED ASTHMA EXACERBATION MERMAID ALGORITHM

~~~mermaid
graph TD
    A["ğŸ« Acute Asthma Exacerbation<br/>Recognition + Rapid Triage"] --> B["ğŸ“Š UpToDate Severity Assessment<br/>Clinical + PEFR + SpO2"]
    
    B --> C{"âš–ï¸ Exacerbation<br/>Severity Level?"}
    
    C -->|MILD| D["ğŸŸ¢ Mild Protocol<br/>PEFR â‰¥70%, Sentences, SpO2 >95%"]
    C -->|MODERATE| E["ğŸŸ¡ Moderate Protocol<br/>PEFR 40-69%, Phrases, SpO2 91-95%"]
    C -->|SEVERE| F["ğŸ”´ Severe Protocol<br/>PEFR <40%, Words Only, SpO2 <91%"]
    C -->|LIFE-THREATENING| G["ğŸš¨ Critical Protocol<br/>Silent Chest, Cyanosis, Exhaustion"]
    
    D --> H["ğŸ’¨ GINA 2025 AIR Therapy<br/>ICS-Formoterol Preferred"]
    E --> I["ğŸ’Š Standard Treatment Triad<br/>SABA + Ipratropium + Steroids"]
    F --> J["ğŸ¥ Intensive Protocol<br/>Continuous Nebs + Magnesium"]
    G --> K["ğŸš¨ Critical Care<br/>ICU + Intubation Ready"]
    
    H --> L["â±ï¸ Reassess 1h<br/>PEFR + Clinical Response"]
    I --> M["â±ï¸ Reassess 1h<br/>Standard Monitoring"]
    J --> N["â±ï¸ Continuous Monitor<br/>Q15min Assessment"]
    K --> O["ğŸ¥ ICU Management<br/>Advanced Life Support"]
    
    L --> P{"ğŸ“ˆ Response<br/>Adequate?"}
    M --> Q{"ğŸ“ˆ Treatment<br/>Response?"}
    N --> R{"ğŸ¯ Critical<br/>Improvement?"}
    
    P -->|GOOD| S["âœ… Continue AIR<br/>Discharge Planning"]
    P -->|POOR| T["â¬†ï¸ Escalate Protocol<br/>Add Systemic Steroids"]
    Q -->|GOOD| U["âœ… Continue Treatment<br/>Transition Planning"]
    Q -->|PARTIAL| V["â¬†ï¸ Increase Frequency<br/>Add Magnesium"]
    Q -->|POOR| W["ğŸš¨ Escalate to Severe<br/>Continuous Treatment"]
    R -->|YES| U
    R -->|NO| O
    
    T --> M
    V --> N
    W --> N
    S --> X{"ğŸ  Discharge<br/>Criteria Met?"}
    U --> X
    
    X -->|YES| Y["ğŸ“‹ GINA 2025 Discharge<br/>AIR + Action Plan"]
    X -->|NO| Z["ğŸ¥ Admit for Observation<br/>Extended Monitoring"]
    
    Y --> AA["âœ… Home with Support<br/>Follow-up Arranged"]
    Z --> BB["ğŸ“Š Inpatient Optimization<br/>Specialist Consultation"]
    O --> BB
    
    AA --> CC["âœ… Asthma Protocol<br/>Complete"]
    BB --> CC
    
    style A fill:#ffcccc
    style F fill:#ffaaaa
    style G fill:#ff6666
    style J fill:#ff8888
    style K fill:#ff4444
    style O fill:#ff6666
    style Y fill:#ccffcc
    style CC fill:#ccffee
~~~

## ASTHMA DYNAMIC CARD SYSTEM

### Card 0 â€“ Initial Assessment & Triage (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« ASTHMA EXACERBATION RECOGNITION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Immediate Recognition Criteria**:     â”‚
â”‚ -  **Acute dyspnea**: Worsening from baselineâ”‚
â”‚ -  **Wheeze**: Audible with/without stethoscopeâ”‚
â”‚ -  **Cough**: Dry or productive        â”‚
â”‚ -  **Chest tightness**: Patient-reported sensationâ”‚
â”‚ -  **Activity limitation**: Unable to perform usual tasksâ”‚
â”‚                                         â”‚
â”‚ **High-Risk Historical Factors**:       â”‚
â”‚ -  **Previous ICU/intubation**: For asthmaâ”‚
â”‚ -  **â‰¥3 ED visits**: In past year       â”‚
â”‚ -  **Recent hospitalization**: Within 12 monthsâ”‚
â”‚ -  **Current steroid use**: Oral prednisoloneâ”‚
â”‚ -  **Poor adherence**: Controller medicationsâ”‚
â”‚ -  **Food allergies**: Especially nuts  â”‚
â”‚                                         â”‚
â”‚ **Vital Sign Priorities**:             â”‚
â”‚ -  **Respiratory rate**: Baseline assessmentâ”‚
â”‚ -  **Heart rate**: Tachycardia common   â”‚
â”‚ -  **Blood pressure**: Pulsus paradoxus >15mmHgâ”‚
â”‚ -  **SpO2**: Continuous monitoring      â”‚
â”‚ -  **Peak flow**: If patient able       â”‚
â”‚                                         â”‚
â”‚ **Differential Considerations**:        â”‚
â”‚ -  **Anaphylaxis**: Acute onset, systemicâ”‚
â”‚ -  **Pneumothorax**: Sudden chest pain  â”‚
â”‚ -  **Pneumonia**: Fever, consolidation  â”‚
â”‚ -  **Foreign body**: Especially childrenâ”‚
â”‚                                         â”‚
â”‚ [Next: Severity classification â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ UpToDate Severity Assessment (Node B â†’ C)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š UPTODATE ASTHMA SEVERITY CLASSIFICATIONâ”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Mild Exacerbation**:                 â”‚
â”‚ -  **Breathlessness**: While walking    â”‚
â”‚ -  **Position**: Can lie down           â”‚
â”‚ -  **Speech**: Complete sentences       â”‚
â”‚ -  **PEFR**: â‰¥70% predicted/personal bestâ”‚
â”‚ -  **SpO2**: >95% room air              â”‚
â”‚ -  **Heart rate**: <100 bpm             â”‚
â”‚ -  **Wheeze**: Moderate, end-expiratory â”‚
â”‚                                         â”‚
â”‚ **Moderate Exacerbation**:             â”‚
â”‚ -  **Breathlessness**: At rest, prefers sittingâ”‚
â”‚ -  **Speech**: Phrases only             â”‚
â”‚ -  **PEFR**: 40-69% predicted           â”‚
â”‚ -  **SpO2**: 90-95%                     â”‚
â”‚ -  **Heart rate**: 100-120 bpm          â”‚
â”‚ -  **Accessory muscles**: Commonly presentâ”‚
â”‚ -  **Wheeze**: Loud throughout exhalationâ”‚
â”‚                                         â”‚
â”‚ **Severe Exacerbation**:               â”‚
â”‚ -  **Breathlessness**: At rest, sits uprightâ”‚
â”‚ -  **Speech**: Words only               â”‚
â”‚ -  **PEFR**: <40% predicted             â”‚
â”‚ -  **SpO2**: <90%                       â”‚
â”‚ -  **Heart rate**: >120 bpm             â”‚
â”‚ -  **Accessory muscles**: Throughout breathingâ”‚
â”‚ -  **Wheeze**: Loud inspiration + expirationâ”‚
â”‚                                         â”‚
â”‚ **Life-Threatening**:                  â”‚
â”‚ -  **Silent chest**: Minimal air movementâ”‚
â”‚ -  **Cyanosis**: Central or peripheral  â”‚
â”‚ -  **Exhaustion**: Poor respiratory effortâ”‚
â”‚ -  **Altered consciousness**: Confusion â”‚
â”‚ -  **Arrhythmias**: Brady/tachycardia   â”‚
â”‚                                         â”‚
â”‚ [Next: Severity-specific treatment â–¶]  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ GINA 2025 AIR Therapy (Node H â†’ L)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’¨ GINA 2025 AIR THERAPY PROTOCOL        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Anti-Inflammatory Reliever 2025[1][5]**:â”‚
â”‚ -  **Preferred**: ICS-formoterol combinationâ”‚
â”‚ -  **Budesonide-formoterol**: 100/6 mcg â”‚
â”‚ -  **Dose**: 1-2 puffs every 20min Ã— 3  â”‚
â”‚ -  **Maximum**: 8-12 puffs in 24h       â”‚
â”‚                                         â”‚
â”‚ **Alternative Track 2 Approach[8]**:    â”‚
â”‚ -  **ICS + SABA**: Take together        â”‚
â”‚ -  **Timing**: ICS immediately after SABAâ”‚
â”‚ -  **Rationale**: Prevents SABA-only risk[14]â”‚
â”‚                                         â”‚
â”‚ **Oxygen Support**:                     â”‚
â”‚ -  **Target SpO2**: â‰¥92% (â‰¥94% pregnancy)â”‚
â”‚ -  **Delivery**: Nasal cannula 2-4L/min â”‚
â”‚ -  **Monitor**: Continuous pulse oximetryâ”‚
â”‚                                         â”‚
â”‚ **Patient Positioning**:                â”‚
â”‚ -  **Preferred**: Sitting upright       â”‚
â”‚ -  **Avoid**: Forcing supine position   â”‚
â”‚ -  **Support**: Pillow table for comfortâ”‚
â”‚                                         â”‚
â”‚ **Response Timeline**:                  â”‚
â”‚ -  **Onset**: 15-30 minutes expected    â”‚
â”‚ -  **Peak effect**: 60-90 minutes       â”‚
â”‚ -  **Reassessment**: At 1 hour mandatoryâ”‚
â”‚                                         â”‚
â”‚ **Monitoring Parameters**:              â”‚
â”‚ -  **PEFR**: Before/after treatment     â”‚
â”‚ -  **Speech ability**: Sentence completionâ”‚
â”‚ -  **Respiratory rate**: Trend analysis â”‚
â”‚ -  **Patient comfort**: Subjective assessmentâ”‚
â”‚                                         â”‚
â”‚ [Next: 1-hour evaluation â–¶]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Standard Treatment Triad (Node I â†’ M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š MODERATE ASTHMA STANDARD PROTOCOL     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Bronchodilator Protocol[4][9]**:      â”‚
â”‚ -  **Albuterol**: 2.5-5mg nebulized q20min Ã— 3â”‚
â”‚ -  **Alternative**: 4-8 puffs MDI + spacerâ”‚
â”‚ -  **Ipratropium**: 0.5mg with each albuterolâ”‚
â”‚ -  **Synergistic effect**: Dual mechanismâ”‚
â”‚                                         â”‚
â”‚ **Systemic Corticosteroids[4][9]**:     â”‚
â”‚ -  **Oral preferred**: Prednisolone 40-60mgâ”‚
â”‚ -  **IV option**: Methylprednisolone 60-125mgâ”‚
â”‚ -  **Timing**: Give early, don't delay  â”‚
â”‚ -  **Onset**: 4-6 hours for effect      â”‚
â”‚                                         â”‚
â”‚ **Oxygen Therapy**:                     â”‚
â”‚ -  **Indication**: SpO2 <92%            â”‚
â”‚ -  **Target**: â‰¥92% (â‰¥95% pregnancy)    â”‚
â”‚ -  **Method**: Nasal cannula or face maskâ”‚
â”‚                                         â”‚
â”‚ **Enhanced Monitoring**:                â”‚
â”‚ -  **Continuous**: SpO2, cardiac rhythm â”‚
â”‚ -  **Q30min**: PEFR, vital signs        â”‚
â”‚ -  **Hourly**: Clinical assessment      â”‚
â”‚ -  **Document**: Treatment response     â”‚
â”‚                                         â”‚
â”‚ **Success Indicators**:                 â”‚
â”‚ -  **PEFR**: >70% predicted after 1h    â”‚
â”‚ -  **Speech**: Full sentences          â”‚
â”‚ -  **SpO2**: >92% stable              â”‚
â”‚ -  **Comfort**: Patient-reported improvementâ”‚
â”‚                                         â”‚
â”‚ **Escalation Triggers**:                â”‚
â”‚ -  **No improvement**: After 1 hour     â”‚
â”‚ -  **Deterioration**: Any parameter     â”‚
â”‚ -  **Patient exhaustion**: Increased work of breathingâ”‚
â”‚                                         â”‚
â”‚ [Next: Response-based decision â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2C â€“ Severe Asthma Intensive Protocol (Node J â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ SEVERE ASTHMA INTENSIVE MANAGEMENT    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **High-Intensity Bronchodilators[9]**:  â”‚
â”‚ -  **Continuous albuterol**: 10-15mg/hr nebulizedâ”‚
â”‚ -  **Ipratropium**: 0.5mg q20min Ã— 3, then q4hâ”‚
â”‚ -  **High-frequency MDI**: 8 puffs q20minâ”‚
â”‚                                         â”‚
â”‚ **IV Corticosteroids[9]**:              â”‚
â”‚ -  **Loading**: Methylprednisolone 125mg IVâ”‚
â”‚ -  **Maintenance**: 60-125mg IV q6h     â”‚
â”‚ -  **High-dose option**: Up to 2mg/kg/dayâ”‚
â”‚                                         â”‚
â”‚ **Magnesium Sulfate[9]**:               â”‚
â”‚ -  **Dose**: 2g IV over 20 minutes      â”‚
â”‚ -  **Indication**: Life-threatening or unresponsive after 1hâ”‚
â”‚ -  **Monitoring**: Blood pressure, respiratory effortâ”‚
â”‚ -  **Mechanism**: Smooth muscle relaxationâ”‚
â”‚                                         â”‚
â”‚ **Advanced Oxygen Support**:            â”‚
â”‚ -  **High-flow oxygen**: 15L non-rebreatherâ”‚
â”‚ -  **Target SpO2**: â‰¥92%                 â”‚
â”‚ -  **Consider HeliOx**: If available     â”‚
â”‚                                         â”‚
â”‚ **Intensive Monitoring**:               â”‚
â”‚ -  **Q15min**: All vital signs, PEFR    â”‚
â”‚ -  **Continuous**: SpO2, cardiac monitorâ”‚
â”‚ -  **ABG consideration**: If poor responseâ”‚
â”‚ -  **Fluid balance**: IV access, hydrationâ”‚
â”‚                                         â”‚
â”‚ **Adjunctive Therapies[19]**:           â”‚
â”‚ -  **Epinephrine**: If anaphylaxis suspectedâ”‚
â”‚ -  **Terbutaline**: 0.25mg SC if MDI/nebulizer impossibleâ”‚
â”‚ -  **Ketamine**: 0.1-2mg/kg bolus for severe casesâ”‚
â”‚                                         â”‚
â”‚ [Next: Critical care evaluation â–¶]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Response Assessment (Node P/Q â†’ X)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ SYSTEMATIC RESPONSE EVALUATION        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Good Response Criteria[9]**:          â”‚
â”‚ -  **PEFR**: >70% predicted sustained    â”‚
â”‚ -  **Speech**: Complete sentences        â”‚
â”‚ -  **SpO2**: >92% on room air â‰¥1 hour    â”‚
â”‚ -  **Respiratory rate**: <25/min         â”‚
â”‚ -  **Heart rate**: <100 bpm              â”‚
â”‚ -  **Wheeze**: Minimal or absent         â”‚
â”‚                                         â”‚
â”‚ **Partial Response**:                   â”‚
â”‚ -  **PEFR**: 40-70% with some improvementâ”‚
â”‚ -  **Speech**: Phrases, still dyspneic   â”‚
â”‚ -  **SpO2**: 90-95% stable              â”‚
â”‚ -  **Some improvement**: But incomplete   â”‚
â”‚                                         â”‚
â”‚ **Poor Response**:                      â”‚
â”‚ -  **PEFR**: <40% or declining          â”‚
â”‚ -  **Speech**: Words only or worse       â”‚
â”‚ -  **SpO2**: <90% despite oxygen        â”‚
â”‚ -  **Exhaustion**: Increasing fatigue    â”‚
â”‚ -  **Silent chest**: Decreasing air movementâ”‚
â”‚                                         â”‚
â”‚ **Escalation Strategies[9]**:           â”‚
â”‚ -  **Increase frequency**: Q15min treatmentsâ”‚
â”‚ -  **Add magnesium**: 2g IV if severe   â”‚
â”‚ -  **Continuous nebs**: For poor responseâ”‚
â”‚ -  **ICU consultation**: Critical care   â”‚
â”‚                                         â”‚
â”‚ **Documentation Requirements**:         â”‚
â”‚ -  **Response timeline**: Each assessmentâ”‚
â”‚ -  **Peak flows**: Before/after treatmentâ”‚
â”‚ -  **Medication doses**: Total amounts   â”‚
â”‚ -  **Decision rationale**: For escalationâ”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4 â€“ GINA 2025 Discharge Protocol (Node Y â†’ AA)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“‹ GINA 2025 ENHANCED DISCHARGE PLANNING â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **Discharge Readiness Criteria[9]**:    â”‚
â”‚ -  **PEFR**: >70% predicted Ã—2h sustainedâ”‚
â”‚ -  **SpO2**: >92% room air Ã—1h stable    â”‚
â”‚ -  **Clinical**: Sentences, minimal wheezeâ”‚
â”‚ -  **Mobility**: Can walk without distressâ”‚
â”‚ -  **Inhaler technique**: Demonstrated correctlyâ”‚
â”‚                                         â”‚
â”‚ **GINA 2025 Medication Strategy[1][6]**: â”‚
â”‚ -  **Preferred**: ICS-formoterol MART approachâ”‚
â”‚ -  **Maintenance**: Same inhaler BID     â”‚
â”‚ -  **Reliever**: Same inhaler PRN        â”‚
â”‚ -  **Step-up**: From triggering level    â”‚
â”‚                                         â”‚
â”‚ **Oral Corticosteroid Course[4][9]**:   â”‚
â”‚ -  **Prednisolone**: 40-50mg daily       â”‚
â”‚ -  **Duration**: 5-7 days               â”‚
â”‚ -  **No taper**: Required for short courseâ”‚
â”‚ -  **Education**: Take with food, complete courseâ”‚
â”‚                                         â”‚
â”‚ **Asthma Action Plan Requirements[9]**:  â”‚
â”‚ -  **Green zone**: Well-controlled, continue maintenanceâ”‚
â”‚ -  **Yellow zone**: Worsening symptoms, increase treatmentâ”‚
â”‚ -  **Red zone**: Severe symptoms, seek urgent careâ”‚
â”‚ -  **Personalized**: Based on patient's triggersâ”‚
â”‚                                         â”‚
â”‚ **Follow-up Coordination**:             â”‚
â”‚ -  **Primary care**: 48-72 hours        â”‚
â”‚ -  **Asthma specialist**: 1-2 weeks if severeâ”‚
â”‚ -  **Return precautions**: Clear instructionsâ”‚
â”‚                                         â”‚
â”‚ **Patient Education Priorities[5][9]**: â”‚
â”‚ -  **Trigger identification**: Environmental controlâ”‚
â”‚ -  **Early warning signs**: When to act â”‚
â”‚ -  **Medication adherence**: Importance of controllersâ”‚
â”‚ -  **Emergency signs**: When to call 911â”‚
â”‚                                         â”‚
â”‚ [Next: Home management â–¶]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## QUALITY METRICS & IMPLEMENTATION

### **Asthma Protocol Key Features:**
- **GINA 2025 AIR Therapy**: Prioritizes ICS-formoterol over SABA-only approach[1][5]
- **UpToDate Severity**: Integrates formal assessment criteria
- **Evidence-based escalation**: Systematic approach to treatment intensification[9]
- **T2 biomarker consideration**: Future integration for severe asthma[13]

### **Quality Targets:**
- **Time to bronchodilator**: <30 minutes from recognition
- **Appropriate steroid use**: >90% compliance with guidelines
- **AIR therapy adoption**: >75% for appropriate patients
- **30-day readmission**: <15% target

### **Technology Integration:**
- **EMR-embedded flowcharts**: Click-through node activation
- **Real-time PEFR tracking**: Automated trend analysis and response assessment
- **Clinical decision support**: Built-in calculators and severity alerts
- **Quality dashboards**: Outcome metrics and compliance monitoring

### **Specialized Services Integration:**
- **Respiratory Therapy**: 24/7 RT coverage with advanced nebulizer protocols
- **Pulmonology consultation**: Same-day availability for severe cases
- **Allergy/Immunology**: Severe asthma and biologic therapy evaluation
- **Pharmacy services**: Inhaler technique education and AIR therapy optimization
